Zavegepant: First Approval

被引：22
作者：
Dhillon, Sohita [1 ]
机构：
[1] Springer Nat, Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand
来源：
DRUGS | 2023年 / 83卷 / 09期
关键词：
NASAL SPRAY; PHARMACOKINETICS; SINGLE; MIGRAINE; SAFETY; MG;
D O I：
10.1007/s40265-023-01885-6
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Zavegepant is a third generation, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by Pfizer, under a license from Bristol-Myers Squibb, for the prevention and treatment of chronic and episodic migraine. In March 2023, zavegepant nasal spray (ZAVZPRET (TM)) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. Clinical development of an oral formulation of zavegepant is currently underway. This article summarizes the milestones in the development of zavegepant leading to this first approval for the acute treatment of migraine with or without aura in adults.
引用
收藏
页码：825 / 831
页数：7
相关论文
共 26 条
  • [1] Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions
    Al-Hassany, Linda
    Goadsby, Peter J.
    Danser, A. H. Jan
    MaassenVanDenBrink, Antoinette
    [J]. LANCET NEUROLOGY, 2022, 21 (03) : 284 - 294
  • [2] Bertz R, 2022, HEADACHE, V62, P108
  • [3] Bertz R, 2022, HEADACHE, V62, P122
  • [4] Bertz R, 2022, HEADACHE, V62, P105
  • [5] Bhardwaj R, 2022, HEADACHE, V62, P101
  • [6] Bhardwaj R, 2022, HEADACHE, V62, P140
  • [7] Bhardwaj R, 2022, CEPHALALGIA, V42, P79
  • [8] Bhardwaj R, 2022, CEPHALALGIA, V42, P92
  • [9] Biohaven P, 2022, PFIZ COMPL ACQ BIOH
  • [10] Biohaven P, 2022, BIOH PFIZ COMPL COLL
123